VANGUARD consortium meeting in Geneva, CH
June 9, 2022
On June 3-4, the VANGUARD consortium finally met in person after two years of online meetings. The meeting, which took place at the Geneva University
New Generation Cell Therapy:
Bioartificial Pancreas to Cure Type 1 Diabetes
Why needed?
Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies.
There is an urgent need for the development of a beta cell replacement therapy that will be available to larger numbers of type 1 diabetic patients.
Our solution
The VANGUARD project aims to generate a vascularized and immune-protected bioartificial pancreas that can be transplanted into non-immuno-suppressed patients by combining advanced tissue engineering strategies.
This approach will yield a cell therapy in the form of an Advanced Therapy Medicinal Product (ATMP), which can significantly improve treatment of type 1 diabetes.
Project overview
News
VANGUARD Ethics Workshop
March 18, 2022
Bio-artificial organs and bio-engineered or bio-printed tissues for transplantation in humans are rapidly being developed. It is anticipated that some applications will be ready for
New publication on the generation of pre-vascularised organoids
January 24, 2022
The VANGUARD consortium recently published collaborative work in the journal Transplant International on the generation of pre-vascularised organoids. The authors from the University of Geneva